Literature DB >> 2966632

Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection.

M H Jouvin1, W Rozenbaum, R Russo, M D Kazatchkine.   

Abstract

Expression of the C3b/C4b receptor (CR1) was studied on erythrocytes of 153 individuals infected with HIV and 104 age-matched normal individuals by measuring the uptake of 125I-labelled monoclonal anti-CR1 antibody. The mean number of CR1 sites on erythrocytes of asymptomatic seropositive individuals (822 +/- 270; mean +/- s.d.) and of patients with persistent generalized lymphadenopathy (PGL; 775 +/- 320) did not differ significantly from that of normal subjects. The number was significantly lower in patients with AIDS-related complex (ARC; 543 +/- 233; P less than 5 x 10(-3)) and further decreased in patients with AIDS (442 +/- 271; P less than 1 x 10(-4)), whether they presented with Kaposi's sarcoma (KS) or opportunistic infections. An additional finding was that of decreased expression of antigenic and functional CR1 in neutrophils from patients with AIDS, as assessed by radioimmunoassay of CR1 in detergent-solubilized cells and the capacity of intact cells to form rosettes with C3b-coated erythrocytes. Low numbers of CR1 on cells from patients with AIDS were not due to occupation of the receptor by C3 fragments on immune complexes. The correlation that was observed between decreased numbers of CR1 on erythrocytes and clinical subpopulations of symptomatic HIV-infected patients suggests that CR1 expression on erythrocytes may represent a valuable marker of the severity and natural history of HIV-associated disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2966632

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

2.  Quantitative western immunoblotting analysis in survey of human immunodeficiency virus-seropositive patients.

Authors:  D G Schiavini; J M Puel; S A Averous; J A Bazex
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

3.  Erythrocyte complement receptor type 1 in non-SLE rheumatic diseases.

Authors:  J H Yen; H W Liu; S F Lin; T P Chen
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

4.  Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon?

Authors:  P E Ruuska; I Ikäheimo; S Silvennoinen-Kassinen; M L Käär; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

5.  Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Authors:  Gülşen Özkaya Şahin; Birgitta Holmgren; Enas Sheik-Khalil; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Fredrik Månsson; Hans Norrgren; Peter Aaby; Eva Maria Fenyö; Marianne Jansson
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

6.  C3b receptor (CR1) genomic polymorphism in rheumatoid arthritis. Low receptor levels on erythrocytes are an acquired phenomenon.

Authors:  A Kumar; A N Malaviya; S Sinha; P S Khandekar; K Banerjee; L M Srivastava
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

Review 7.  Complement Receptor 1: disease associations and therapeutic implications.

Authors:  Rohan Khera; Nibhriti Das
Journal:  Mol Immunol       Date:  2008-11-11       Impact factor: 4.407

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.